Navigation Links
GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors

ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship.

Gerd Zettlmeissl has more than 20 years of experience in developing and commercializing vaccines. He spent almost 10 years in executive positions at Intercell AG, first as its Chief Operating Officer from 2001 to 2005 and then as its Chief Executive Officer from 2005 until May  2011. Under his leadership, the company received international approval for the novel Japanese encephalitis vaccine, IXIARO®/JESPECT®, formed major strategic alliances with leading pharmaceutical companies, completed several financings, was elected as 'Technology Pioneer' at the World Economic Forum in 2009 and received the European Biotechnica Award in 2006. Before his tenure at Intercell, he served as the international Head of Industrial and Quality Operations at Chiron Vaccines, and Managing Director of Chiron Behring GmbH & Co. He currently serves on the Boards of several biotechnology companies including Aeras, an organization dedicated to the development of tuberculosis vaccines. He holds a Doctorate from the University of Regensburg.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," said Michel Greco , Chairman of the Board of Directors of GlycoVaxyn. "After having chaired the Board for more than seven years, I will work very closely with Gerd to ensure a smooth transition."

Philippe Dro , Chief Executive Officer of GlycoVaxyn added, "The changes to the Board and the appointment of Gerd will contribute to support GlycoVaxyn's strategic ambitions to become a major player in the development of a new generation of vaccines, particularly following our recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. We know Gerd very well and share with him a common passion for the development of innovative vaccines. After several years of close collaboration with Michel on this exciting project over the years, I would like to sincerely thank him, on behalf of the whole team, for his strong commitment and support."

About GlycoVaxyn AGGlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoprotein conjugates in a biological process that circumvents many of the challenges and uncertainties involved in currently/chemical used methods. In addition to the clinical stage Shigella vaccine, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcus aureus infections. GlycoVaxyn recently entered collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. GlycoVaxyn is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.  For further information, visit FlammGlycoVaxyn AG

Russo Partners, LLCTel: +41 44 733 8595


SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer CropScience Announces Seed Innovation at Pollinator Summit
2. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
3. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
4. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
5. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
6. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
7. Research and Markets Announces Addition of the "Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment" Report to its Offering
8. Research & Markets Announces the Release of 'Analog Devices ADXL362 3-axis Micropower MEMS Accelerometer Reverse Costing Analysis'
9. Research & Markets Announces the Release of STMicroelectronics LSM303D 6-Axis Electronic Compass - Reverse Costing Analysis
10. Pamlab Announces Agreement for Sale of Business to Nestle Health Science
11. Elsevier Announces the Launch of a New Journal: Methods in Oceanography
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
Breaking Biology News(10 mins):